Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The AbsorbaSeal Vascular Closure Device Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03730571
Recruitment Status : Terminated (Insufficient closure)
First Posted : November 5, 2018
Last Update Posted : January 6, 2021
Sponsor:
Collaborator:
CyndRx, LLC
Information provided by (Responsible Party):
ID3 Medical

Brief Summary:
This study investigates the efficacy and safety of the AbsorbaSeal 6Fr Vascular Closure device (VCD) for the closure of access site of patients requiring percutaneous diagnostic or interventional procedures. An expected total of 50 patients will be enrolled in this study. A total of 12 patients (4 patients per site) will be treated as roll-in phase, prior to enrollment of the first patient. The primary objective of this study is to assess the safety and effectiveness of the AbsorbaSeal 6Fr VCD. Enrollment into this study will include anatomically eligible patients requiring diagnostic and interventional procedures. Following physician training, patients will be enrolled. Efficacy and safety analyses will be based on these patients.Patients will be followed procedurally to discharge, at one month, (follow-up commitment). Secondary objectives are to further characterize adverse events (serious and non-serious), clinical utility measures and health-related quality of life.

Condition or disease Intervention/treatment Phase
Peripheral Arterial Disease Device: AbsorbaSeal 6Fr Vascular Closure Device Not Applicable

Detailed Description:

With the increased number of percutaneous interventions being performed in outpatient settings there is a growing need to obtain faster, safer, and more secure hemostasis following these outpatient procedures. CyndRx believes an improved VCD will lead to more widespread use and ultimately improve patient outcomes. The AbsorbaSeal Vascular Closure Device (ABS-6) has been developed to meet this need. The ease of use and automatic deployment of the device will eliminate the learning curve associated with the use of VCDs. The active closure system used in the ABS-6 ensures a secure closure with every deployment. The composition of the seal used is completely bio-absorbable and does not require the use of adjunct materials (i.e. collagen, sutures, staples, etc.) needed in many of the devices currently available.

The First In Man (FIM) trial demonstrated the safety and efficacy of the ABS-6 system in humans (N=20). To further evaluate the safety and efficacy, up to 50 patients will be enrolled in the CP002CE-study.

The primary objective of this study is to assess the safety and effectiveness of the AbsorbaSeal 6Fr VCD. Enrollment into this study will include anatomically eligible patients requiring diagnostic and interventional procedures. Patients will be followed procedurally to discharge, at one month, (follow-up commitment). Secondary objectives are to further characterize adverse events (serious and non-serious), clinical utility measures, and health-related quality of life.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Prospective, Multi-center, Non-Randomized Controlled Trial of Vascular Closure Using the AbsorbaSeal 6 French Vascular Closure Device
Actual Study Start Date : August 16, 2017
Actual Primary Completion Date : April 11, 2019
Actual Study Completion Date : April 11, 2019

Arm Intervention/treatment
Experimental: AbsorbaSeal 6Fr Vascular Closure Device
Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device
Device: AbsorbaSeal 6Fr Vascular Closure Device
Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device




Primary Outcome Measures :
  1. Treatment success [ Time Frame: 30 days post-index procedure ]
    Composite of (1) procedural technical success (successful vascular access and ABS-6 delivery, deployment and catheter removal), (2) absence of vascular complications (arteriovenous fistula, femoral neuropathy, hematoma >6cm, hemorrhage, infection, lymphocele, thrombosis/occlusion/distal emboli/stenosis, vascular injury) (3) absence of major adverse events (all-cause death, cardiac morbidity, neurological complications, renal failure, respiratory complications, secondary intervention for groin complications)


Secondary Outcome Measures :
  1. Number of Adverse events [ Time Frame: 30 days post-index procedure ]
    All adverse events will be monitored. A serious adverse event is defined as an event that results in death, is life threatening, requires inpatient hospitalization or that prolongs hospitalization, results in persistent or significant disability/incapacity

  2. Volume of contrast media used during index procedure [ Time Frame: Intraoperative ]
    Volume of contrast media used (ml)

  3. Fluoroscopy time during index procedure [ Time Frame: Intraoperative ]
    Fluoroscopy time (min)

  4. Estimated blood loss during index procedure [ Time Frame: Intraoperative ]
    Estimated blood loss (ml)

  5. Time to hemostasis after index procedure [ Time Frame: Intraoperative ]
    Time to hemostasis (min)

  6. Total procedure time of index procedure [ Time Frame: Intraoperative ]
    Total procedure time (min)

  7. Anesthesia time of index procedure [ Time Frame: Intraoperative ]
    Anesthesia time (min)

  8. Total time of initial hospitalization stay [ Time Frame: Up to 1 month post-index procedure ]
    Total time of initial hospitalization stay (h:min)

  9. Analgesic usage after index-procedure [ Time Frame: 1-day post-index procedure ]
    Arterial access site pain-related analgesic usage after index procedure until patient discharge

  10. Pain Evaluation [ Time Frame: 1-day post-index procedure and 1 month follow-up ]
    Self-reported groin pain scale (0 (no pain) - 10 (excessive pain))



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient is between 18 and 85 years of age
  • Male and Female
  • Patient/legal representative provides written informed consent
  • Patient is scheduled for a coronary or peripheral diagnostic or interventional procedure
  • Patient is able to undergo emergent vascular surgery if a complication related to the VCD necessitates such surgery
  • Patient has a 6 french arterial puncture located in the common femoral artery
  • Target vessel has a lumen diameter ≥ 5 mm
  • Patient is willing and able to complete follow-up
  • Catheterization procedure is planned and elective

Exclusion Criteria:

  • Prior target artery closure with any closure device or closure with manual compression ≤ 30 days prior to the cardiac or peripheral catheterization procedure
  • Patients with a history of significant bleeding or with any known or documented bleeding disorders, such as Thrombocytopenia (with < 100,000 platelet count), Von Willebrand's disease, anemia (Hgb < 10 g/dL, Hct < 30%), thrombasthenia, decreased fibrinogen (< 200 mg/dL), and Factor V deficiency
  • Acute ST-elevation myocardial infarction ≤ 48 hours prior to the cardiac or peripheral catheterization procedure
  • Patient is ineligible for in-lab catheterization lab introducer sheath removal
  • Concurrent participation in another investigational device or drug trial
  • Thrombolytic therapy (e.g. streptokinase, urokinase, t-PA) ≤ 24 hours prior to the cardiac or peripheral catheterization procedure
  • Evidence of a preexisting hematoma, arteriovenous fistula, or pseudoaneurysm at the access site prior to start of femoral artery closure procedure
  • Prior femoral vascular surgery or vascular graft in region of access site or contralateral common femoral artery
  • The targeted femoral artery is tortuous or requires a sheath length > 10 cm
  • Patient is pregnant or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03730571


Locations
Layout table for location information
Belgium
O.L.V. Hospital
Aalst, Belgium, 9300
Imelda Hospital
Bonheiden, Belgium, 2820
A.Z. Sint-Blasius
Dendermonde, Belgium, 9200
Sponsors and Collaborators
ID3 Medical
CyndRx, LLC
Investigators
Layout table for investigator information
Principal Investigator: Koen Deloose, MD ID3 Medical
Layout table for additonal information
Responsible Party: ID3 Medical
ClinicalTrials.gov Identifier: NCT03730571    
Other Study ID Numbers: CP002CE
First Posted: November 5, 2018    Key Record Dates
Last Update Posted: January 6, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Peripheral Vascular Diseases
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases